We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.68 | 0.70% | 98.18 | 445 | 11:41:18 |
From May 2019 to May 2024
By Erin McCarthy
Actavis PLC (ACT) said Thursday that a U.S. federal court has ruled that its generic version of Novartis' Exelon Patch infringes certain patents.
Exelon Patch is a prescription medicine used to treat people with mild to moderate dementia associated with Alzheimer's or Parkinson's disease.
Actavis said in a statement that it is reviewing the decision of the U.S. District Court for the District of Delaware and will evaluate all available options, including an appeal.
Actavis' new drug application for its generic version of Exelon Patch is currently pending with the U.S. Food and Drug Administration, the company said.
Earlier this month, Vivus Inc. (VVUS) said it filed a patent-infringement lawsuit against Actavis PLC (ACT) alleging that the drug maker's planned generic version of weight-loss drug Qsymia infringes its patents.
Write to Erin McCarthy at erin.mccarthy@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
